Aus Bio Ltd
Overview
Established in March 2000, Aus Bio an unlisted public company, is developing human and veterinary related biomedical and pharmaceutical products.
Aus Bio’s scientific team identifies naturally occurring bioactive compounds, initially to use as scientific leads. As a result of scientific success a number of projects are at various stages of both research and product development.
The most advanced of which is:
- Project MD 920 Wound Healing (Chronic Venous Ulcers). The Company has successfully completed a Phase I Clinical Trial Study. Planning for a Phase IIb/III Study has been completed and Institutional Ethics approval to commence the study has been granted. Between 10 and 20 Australian Recuitment Sites involved in the study which may take up to two years to complete.
- MD 922
- Project MD 960 The Development of Novel Treatments for the Managements of Diabetes Mellitus and Insulin Resistance. Orally bioavailable therapeutic synthesized. Mode of action as an insulin sensitizer. Patent protection extended. Additional PoC studies confirm efficacy and this project is anticipated to enter a Clinic within 12 months.
- Project PC 2000 ‘Development of Immune Modulators for Chronic Hepatitis B & C Infections’. Lead compounds identified. PoC studies have shown the lead compound to activity in a HCV replicon model also in a breast cancer cell line. Specific cytokine assays developed.
- Project MD 990 The Development of Novel Pharmaceuticals for Specific Acute and Chronic Respiratory Conditions. Lead compounds identified. PoC studies underway. Compound safe and non toxic.
- MD 990
Number of employees
5
Specific focus of company
To improve human and veterinary health outcomes through the identification and development of new drug candidates for specific chronic disease states
Core Business Definition
Pharmaceuticals
Competitive advantages
As a small highly focussed Company, Aus Bio, through a nationally recognised research team, is flexible, adaptable and responds promptly to changing research circumstances. The Company’s Projects all focus on areas of unmet clinical need where large markets exist for safe and effective pharmaceutical products.
Number of employees: 5
Main business focus/
Listing by sector:
- Drug Discovery & Development
Competitive Advantages
As a small highly focussed Company, Aus Bio, through a nationally recognised research team, is flexible, adaptable and responds promptly to changing research circumstances. The Company’s Projects all focus on areas of unmet clinical need where large markets exist for safe and effective pharmaceutical products.
Technology/IP
The identification of a number of biologically active substances as scientific leads has allowed Aus Bio’s focussed research team to apply chemical mimicking techniques to these leads to result in the development of a number of Lead Compounds for application in various areas of human disease.
Partnering Opportunities
Aus Bio offers opportunities to other interested parties, corporate or otherwise to discuss, and if appropriate, cement partnership possibilities in the areas of development of novel treatments for wound healing, diabetes mellitus, chronic Hepatitis B & C, post viral cough syndrome and various aspects of animal husbandry including improved growth and food conversion ratios through the use of non antibiotic feed additives.
Contact Details
| Contact person | Peter Jenkins |
|---|---|
| Job Title | Executive Director |
| Address | Unit 1/27 Normanby Road |
| City/Suburb | Notting Hill, |
| State | Victoria |
| ausbio@bigpond.com | |
| Phone | +61 3 9562 6844 |
| Fax | +61 3 9558 8799 |
| Website | http://www.ausbio.com.au |
